Navigation Links
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Date:8/29/2007

EXPANDED CLINICAL PROGRAM SUPPORTED BY PROMISING RESULTS FROM COMPLETED

TRIAL

TORONTO, Aug. 29 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced completion of a proof of concept clinical trial in Acute Myeloid Leukemia (AML), and expansion of its GTI-2040 development program in this indication, with initiation of a more advanced Phase II clinical trial with GTI-2040 and high dose Ara-C (HiDAC) in refractory and relapsed AML.

The advanced Phase II clinical trial, which is now underway, includes both an efficacy study and a novel additional study to measure intracellular target activities and pharmacological synergies between the two agents. In the first stage of the 60 patient trial, the pharmacologic and target related activity of GTI-2040 and HiDAC will be evaluated in two groups, to determine the contribution of each agent alone and in combination. The second stage of the trial will provide efficacy evaluation in a larger patient population. Lorus expects the clinical trial to be completed by the end of 2008.

The decision by Lorus to advance clinical development of GTI-2040 is based on the encouraging results from our recently completed proof of concept study of GTI-2040 in combination with HiDAC in patients with refractory and relapsed AML. This clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Moreover, the clinical responses correlated with downregulation of R2, the cellular target of GTI-2040, and were further supported by demonstration of intracellular GTI-2040 in circulating and bone marrow leukemic cells. Complete results from the clinical trial are expected to be presented by the investigators in
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. BioRobot MDx standardize your automated protocols in clinical laboratories
11. What patients want: A story of choice, clinical trials & evidence-based medicine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...o Speak at Economic Club of Canada , ...009 -- Ambassador to Speak at Economic Club of Can... for International Investment, and Chairman and CE...phy of David Appia go to www.investinfrance.org ....t with press to discuss recent pro-business initia...
(Date:11/25/2009)...portlinker.comannouncesthatanewmarketresearchrepor...lMarketAnalysisandForecaststo2013 ,, http://w...ket-Analysis-and-Forecasts-to-2013.html ,, Bra..., Summary ,, Thereportprovidesdetailedanalysi...ilbioethanolmarketinparticular.Italsohelpsinanalyz...
(Date:11/24/2009)...o also Visit Detroit , (V...French Ambassador for International Investment, an... , , , ,What: Ambassador Appia is available to me...atives adopted by France to further develop the fi...ion and development., , ,When: Available for Inter...
(Date:11/24/2009)...RNewswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq:...heNasdaqStockMarketthattradinginthecompany,scommon...-NSEwillbefiledwiththe,SecuritiesandExchangeCommis...gonNasdaq,unlessthecompanyfilesanappealtotheNasdaq...anappeal,which,willstaythesuspensionanddelistingth...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...ov. 12 /PRNewswire/ - The Center for Molecular,Med... Midwest-based,laboratories to offer the Veridex C...uffering from metastatic breast cancer (also calle...earch System is the first diagnostic test to,autom...s (CTCs) in the,bloodstream from a blood sample. S...
...2 Aktiv-Dry LLC has been awarded,an SBIR research...vention,(CDC) to explore the formulation of certai...ht eventually be used to treat pulmonary disorders...is the principal investigator. As an intervention...treating RSV include delivering to the respiratory...
...ov. 12 Alma Lasers Ltd., a global,leader in the d...thetic,laser, light-based, and radiofrequency syst...,s 9th fastest growing company in the Deloitte Tec...by Deloitte Brightman Almagor.,Rankings are based ...rom,2002-2006. Howard Kelly, Alma Laser,s CEO, co...
Other Biology Technology:Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer 2Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV 2Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award 2
(Date:11/24/2009)...rican College of Medical Toxicology (ACMT) have si...n of the Journal of Medical Toxicology (JMT), th... 2010. It was previously published by the Univers...dical Toxicology , an international, peer-reviewed...d practice of medical toxicology. The quarterly j...
(Date:11/24/2009)...mber 24, 2009) New research on bacterial communit...eveals predictable temporal patterns, suggesting t...ers for monitoring climate change in the polar reg...edings of the National Academy of Sciences Early ...ix rivers shifted synchronously over time, correla...
(Date:11/23/2009)... November 23, 2009 Applied mathematicians dissec...ncifolia ), a characteristic long leaf with a sadd...along the edges. The simple cause of the lily,s fa...ing during differential growthwas revealed by usin...bons. , Haiyi Liang, a postdoctoral student at H...
Breaking Biology News(10 mins):Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2The cause behind the characteristic shape of a long leaf revealed 2Comprehensive Online Video Added to Media Categories Tracked by BurrellesLuce 53077 1Comprehensive Online Video Added to Media Categories Tracked by BurrellesLuce 53077 2Comprehensive Online Video Added to Media Categories Tracked by BurrellesLuce 53077 3Video 3A New Way RA 28TM 29 Talk Show Premieres Online for People Living With Rheumatoid Arthritis 28RA 29 13252 1Video 3A New Way RA 28TM 29 Talk Show Premieres Online for People Living With Rheumatoid Arthritis 28RA 29 13252 2Video 3A New Way RA 28TM 29 Talk Show Premieres Online for People Living With Rheumatoid Arthritis 28RA 29 13252 3Video 3A New Way RA 28TM 29 Talk Show Premieres Online for People Living With Rheumatoid Arthritis 28RA 29 13252 4New ACTICOAT 28TM 29 Silver Coated Anti microbial Barrier Dressing Receives 510 28k 29 Clearance from the US FDA 53070 1New ACTICOAT 28TM 29 Silver Coated Anti microbial Barrier Dressing Receives 510 28k 29 Clearance from the US FDA 53070 2New ACTICOAT 28TM 29 Silver Coated Anti microbial Barrier Dressing Receives 510 28k 29 Clearance from the US FDA 53070 3New ACTICOAT 28TM 29 Silver Coated Anti microbial Barrier Dressing Receives 510 28k 29 Clearance from the US FDA 53070 4
...s and most their contemporaries were not wiped out...o a paleontologist who says multiple meteor impact... culminated in the end of the Cretaceous Period. ... lesser and earlier of a series of meteors and vol...e than 500,000 years, say Princeton University pal...
...une response to an avian influenza vaccine with do...ded a chemical mixture known as MF59. The research...Infectious Diseases, now available online. , MF ...immune system,s ability to respond to a stimulus. ...ted H9N2 influenza vaccines--not the H5N1 virus cu...
...made international headlines in May 2006 when Coli...us illegal egg collector, died after falling from ...g. The Royal Society for the Protection of Birds e...e species are targeted by collectors. Classical ec...unlikely to extinguish a species because the cost ...
Other Biology News:'Fruit fly dating game' provides clues to our reproductive prowess 2'Fruit fly dating game' provides clues to our reproductive prowess 3A human taste for rarity spells disaster for endangered species 2A human taste for rarity spells disaster for endangered species 3
SUPERaseIn from Ambion
BD FACSAria Cell Sorting System from BD Biosciences - Immunocytometry Systems
EGTA from Research Organics, Inc.
...ate chemiluminescence efficiencies and the chemist...ve the added benefit that they require simple trig...ckground signal. This benefit has been exploited t...lications. These compounds can also be easily modi...
Biology Products: